Core Viewpoint - Waters Corporation has received overwhelming shareholder approval for the issuance of shares to Becton, Dickinson and Company in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters, with the transaction expected to close on February 9, 2026 [1][2][3] Group 1: Shareholder Approval and Transaction Details - Approximately 99% of shares present at the Special Meeting voted in favor of the share issuance to BD shareholders [3] - The transaction has received all required regulatory approvals and a favorable Private Letter Ruling from the IRS regarding U.S. federal income tax consequences [2] - The expected closing date for the transaction is February 9, 2026, subject to customary closing conditions [2] Group 2: Future Outlook and Company Vision - The company aims to create meaningful value for patients, customers, employees, and shareholders as it transitions into a leader in life sciences and diagnostics [2] - The upcoming Q4 2025 financial results will be released on February 9, 2026, coinciding with the expected transaction close [4] - Waters Corporation has been a global leader in analytical instruments and technologies for over 65 years, serving various scientific fields [5]

Company Overview - Bausch + Lomb Corporation is a global leader in eye health, operating across vision care, pharmaceuticals, and surgical segments, leveraging a diverse product portfolio and international distribution to address a wide range of ocular conditions and procedures [8] - The company generates revenue primarily through the sale of proprietary and generic eye health products to healthcare professionals, clinics, and retail channels worldwide, serving ophthalmologists, optometrists, surgical centers, and consumers seeking vision correction and eye health solutions globally [12] Financial Performance - For the third quarter, Bausch + Lomb reported revenue of $1.28 billion, reflecting a 7% year-over-year increase, driven by growth across its Vision Care, Pharmaceuticals, and Surgical segments [9] - Adjusted EBITDA for the same quarter rose to $243 million, up from $212 million a year earlier, with management increasing full-year adjusted EBITDA guidance, indicating confidence in execution despite external challenges [9] Market Position and Stock Performance - As of the latest report, Bausch + Lomb's stock price was $15.69, down 9% over the past year, which is significantly below the S&P 500's 12% gain [4][5] - The company's stock remains volatile, and the recent full exit by DSC Meridian Capital suggests a lower conviction in the healthcare-specific investment compared to the fund's other holdings in infrastructure and commodity-linked sectors [10] Investment Sentiment - Bausch + Lomb is not considered a turnaround story but shows signs of durability with a diversified revenue base, expanding product pipeline, and improving profitability [11] - The risk associated with the company is less about its fundamentals and more about market sentiment, as investors have been quick to trade around volatility rather than hold [11]

Core Insights - Danaher Corporation (DHR) is a global leader in science and technology, focusing on innovation in life sciences, diagnostics, and biotechnology, with a market cap of $152.4 billion [1] Performance Overview - DHR has underperformed the broader market over the past 52 weeks, with shares declining 8.4%, while the S&P 500 Index gained 14.5% [2] - Year-to-date, DHR's stock is down 4.4%, compared to a 16.5% return for the S&P 500 [2] - DHR has also lagged behind the iShares U.S. Healthcare ETF, which saw a 3.4% increase over the past 52 weeks and a 10.3% rise year-to-date [3] Recent Financial Results - DHR's shares rose 5.9% following impressive Q3 results, with revenue increasing 4.4% year-over-year to $6.1 billion, surpassing consensus estimates [4] - The adjusted EPS for Q3 was $1.89, improving 10.5% from the previous year and exceeding analyst expectations of $1.71 [4] - Key contributors to the positive performance included DBS-driven execution, momentum in the bioprocessing business, and better-than-expected respiratory revenue at Cepheid [4] Future Earnings Expectations - For the current fiscal year ending in December, analysts expect DHR's EPS to grow 3.2% year-over-year to $7.72 [5] - DHR has a mixed earnings surprise history, topping consensus estimates in three of the last four quarters [5] Analyst Ratings - Among 22 analysts covering DHR, the consensus rating is a "Strong Buy," with 18 "Strong Buy" and four "Hold" ratings [5] - Recently, Wells Fargo maintained an "Equal Weight" rating on DHR and raised its price target to $230, indicating a potential upside of 4.8% from current levels [6]

Core Viewpoint - Revvity, Inc. (RVTY) is expected to report its first-quarter 2025 results on April 28, with a consensus estimate for revenues at $662.2 million, reflecting a 1.9% increase year-over-year, while earnings per share (EPS) is projected at 96 cents, indicating a 2% decline year-over-year [1][2]. Q1 Estimates - The Zacks Consensus Estimate for revenues is $662.2 million, up 1.9% from the prior-year quarter [1] - The consensus mark for earnings is 96 cents per share, indicating a deterioration of 2% year-over-year [1] - Organic top-line growth is expected to be 3-5% in Q1, with 19% of full-year adjusted EPS guidance of $4.90-$5.00 anticipated in this quarter [2] Diagnostics Segment - The Diagnostics segment sales improved 6% organically in the fourth quarter, with strong performance expected to continue in Q1, driven by growth in Immunodiagnostics and Reproductive Health [3] - Immunodiagnostics is projected to grow in high-single digits, supported by strong commercial execution [3] - The estimated revenue for the Diagnostics segment is $324.8 million, down 6.4% year-over-year [6] Life Sciences Segment - The Life Sciences business improved 5% organically in the last reported quarter, primarily driven by recovery in pharma/biotech customer activity [7] - The estimated revenue for the Life Sciences segment is $338 million, up 11.6% year-over-year [8] - New offerings, Signals Clinical and Signals Synergy, are likely to drive adoption of Signals software during Q1 [7] Other Factors to Consider - Revvity announced an expansion of its work with Genomics England to advance genomic initiatives, which may boost newborn screening [9] - The launch of the TotalSeq Phenocyte single-cell protein profiling solution in collaboration with Scale Biosciences may have contributed additional revenues for the Life Sciences segment [10] - The company generates a portion of its sales from China, which is a crucial growth factor for its business in Asia [11] Earnings Beat Likely - The model predicts an earnings beat for Revvity, with an Earnings ESP of +0.52% [12]